Assenagon Asset Management S.A. purchased a new stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 4,425 shares of the medical research company's stock, valued at approximately $1,078,000.
Several other large investors have also recently bought and sold shares of the stock. LPL Financial LLC boosted its holdings in shares of Bio-Rad Laboratories by 34.3% during the fourth quarter. LPL Financial LLC now owns 5,195 shares of the medical research company's stock worth $1,707,000 after acquiring an additional 1,326 shares during the period. Blackhawk Capital Partners LLC. lifted its holdings in Bio-Rad Laboratories by 190.5% during the 4th quarter. Blackhawk Capital Partners LLC. now owns 2,176 shares of the medical research company's stock worth $715,000 after purchasing an additional 1,427 shares during the last quarter. O Shaughnessy Asset Management LLC bought a new stake in Bio-Rad Laboratories in the 4th quarter valued at $245,000. Truist Financial Corp boosted its stake in Bio-Rad Laboratories by 0.8% in the 4th quarter. Truist Financial Corp now owns 9,186 shares of the medical research company's stock valued at $3,018,000 after purchasing an additional 72 shares during the period. Finally, Two Sigma Investments LP grew its holdings in Bio-Rad Laboratories by 70.3% in the 4th quarter. Two Sigma Investments LP now owns 2,050 shares of the medical research company's stock valued at $673,000 after buying an additional 846 shares in the last quarter. 65.24% of the stock is owned by institutional investors.
Bio-Rad Laboratories Price Performance
Shares of BIO traded up $1.22 during trading hours on Thursday, hitting $231.68. 348,683 shares of the company were exchanged, compared to its average volume of 392,770. The company has a market cap of $6.30 billion, a price-to-earnings ratio of -3.04 and a beta of 0.93. Bio-Rad Laboratories, Inc. has a fifty-two week low of $211.43 and a fifty-two week high of $387.99. The company has a quick ratio of 4.43, a current ratio of 5.99 and a debt-to-equity ratio of 0.18. The firm's fifty day moving average is $235.93 and its 200 day moving average is $279.87.
Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical research company reported $2.54 earnings per share for the quarter, topping the consensus estimate of $1.73 by $0.81. The business had revenue of $585.40 million during the quarter, compared to analysts' expectations of $573.01 million. Bio-Rad Laboratories had a negative net margin of 85.16% and a positive return on equity of 4.32%. Bio-Rad Laboratories's revenue was down 4.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.30 earnings per share. On average, equities analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
BIO has been the subject of a number of research reports. Royal Bank Of Canada dropped their target price on Bio-Rad Laboratories from $409.00 to $392.00 and set an "outperform" rating for the company in a report on Friday, May 2nd. UBS Group lowered their price target on shares of Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Citigroup dropped their price objective on shares of Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Wells Fargo & Company cut their price objective on shares of Bio-Rad Laboratories from $260.00 to $245.00 and set an "equal weight" rating for the company in a report on Monday, June 9th. Finally, Wall Street Zen cut shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a report on Sunday, June 8th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $324.25.
Read Our Latest Stock Report on BIO
About Bio-Rad Laboratories
(
Free Report)
Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.
Recommended Stories
Before you consider Bio-Rad Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Rad Laboratories wasn't on the list.
While Bio-Rad Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
